42 results on '"Clements, Philip J."'
Search Results
2. Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease
3. Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among African American Participants of SLS I and II
4. Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
5. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18
6. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II
7. Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium
8. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
9. Improved Transplant-Free Survival in Patients With Systemic Sclerosis-Associated Pulmonary Hypertension and Interstitial Lung Disease
10. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
11. Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise
12. Work productivity in scleroderma: Analysis from the University of California, Los Angeles scleroderma quality of life study
13. A one‐year, phase I/IIa, open‐label pilot trial of imatinib mesylate in the treatment of systemic sclerosis–associated active interstitial lung disease
14. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group
15. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study
16. Skin score: A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis
17. A Semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis
18. Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study
19. Reliability and validity of the university of california, los angeles scleroderma clinical trial consortium gastrointestinal tract instrument
20. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument
21. Correlation of the degree of dyspnea with health‐related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study
22. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis
23. Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial
24. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial
25. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial
26. Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis
27. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial
28. On Choice of Subjects and Replicates in Estimating Among and Within Subject Variation
29. On Encoding Values for Data Recorded asX ≥C
30. Abnormalities of Renal Physiology in Systemic Sclerosis
31. Predictors of psychosocial adjustment in systemic sclerosis
32. Cyclosporine in systemic sclerosis. results of a forty-eight–week open safety study in ten patients
33. Comparison of auranofin, methotreaxate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial
34. A syndrome resembling progressive systemic sclerosis after bone marrow transplantation
35. Association of HLA Antigen A9 with Progressive Systemic Sclerosis (Scleroderma)
36. The arthropathy of advanced progressive systemic sclerosis
37. Randomized, Double‐Blind, Placebo Controlled Trial of Low‐Dose Pulse Methotrexate in Psoriatic Arthritis
38. Comment on the article by Furst et al
39. Muscle disease in progressive systemic sclerosis. diagnostic and therapeutic considerations
40. Home central venous hyperalimentation in fifteen patients with severe scleroderma bowel disease
41. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study
42. Lymphocyte characteristics in rheumatic patients and the effect of azathioprine therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.